longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Bernstein Sticks to Their Hold Rating for Agilon Health (AGL)

Tip Ranks
May 27, 2026 at 11:01 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Bernstein analyst Lance Wilkes has maintained a Hold rating on Agilon Health (AGL) with a price target of $86.00. Wilkes, a 4-star analyst, has an average return of 7.9% and a 59.65% success rate. Agilon Health also received a Hold rating from Barclays, while Benchmark Co. maintained a Buy rating on May 21.

Bernstein analyst Lance Wilkes maintained a Hold rating on Agilon Health today and set a price target of $86.00.

Memorial Day Sale – Claim 70% Off TipRanks

  • Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
  • Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

According to TipRanks, Wilkes is a 4-star analyst with an average return of 7.9% and a 59.65% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as CVS Health, Cigna, and HCA Healthcare.

In addition to Bernstein, Agilon Health also received a Hold from Barclays’s Andrew Mok CFA in a report issued yesterday. However, on May 21, Benchmark Co. maintained a Buy rating on Agilon Health (NYSE: AGL).

Login to unlock332characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
  • Apr 7, 2026 at 10:32 PMReminder: Key events to watch intraday (all times Beijing Time)
  • Apr 1, 2026 at 11:11 PMEli Lilly's Oral Weight-Loss Drug Foundayo Approved, the Only One That Can Be Taken Anytime Without Fasting
  • Mar 9, 2026 at 04:15 PMHandshake and reconciliation! Novo Nordisk withdraws lawsuit, Wegovy officially launches on the Hims & Hers platform
  • Feb 26, 2026 at 12:54 PMBeigene's Q4 revenue increased by 33% year-on-year, turning a profit for the full year, with Baiyueze achieving a record…

Related Stocks

agilon health

agilon health

USAGL

+2.91%

AllianceBernstein

AllianceBernstein

USAB

CVS Health

CVS Health

USCVS

LongbridgeAI